In parallel to the clinical observations, the cell viability of CDCA2-KO cells was equally affected by CHOP and B-CHOP treatment in accordance with the lack of difference in outcome between the two treatment arms for DLBCL patients with low CDCA2 expressions. This evidence concerns the gene CDCA2 and diffuse large B-cell lymphoma.